🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. ziltivekimab, Placebo (ziltivekimab C)

    NovoThirteen

    Heart failure with mildly reduced or preserved ejection fraction and systemic inflammation

    phase 3 small molecule active

    1 trial

  2. ziltivekimab, Ziltivekimab

    NovoThirteen

    The medical condition we are investigating is type 1 AMI (STEMI and NSTEMI). Ziltivekimab is a human monoclonal antibody directed against the interleukin-6 (IL-6) ligand, and currently available clinical data support that ziltivekimab once-monthly reduces inflammation as measured by highsensitivity C-reactive protein (hs-CRP). With the recent proof-of-concept that hs-CRP reduction through inhibition of an upstream pathway leads to reduction in cardiovascular events, it is reasonable to expect that similar inhibition of IL-6 with ziltivekimab also reduces CV risk.The aim of the current study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when initiated as early as possible in adult patients with ST-elevation and non-ST-elevation myocardial infarction

    phase 3 small molecule active

    1 trial

  3. zodasiran Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  4. -

    Lacuna Pharma Pty Ltd

    Myocardial Infarction, Acute Heart Failure, Left Sided

    phase 2 small molecule active

    1 trial

  5. -

    The George Institute

    Cytomegalovirus infection post allogeneic allogeneic HLA-identical familial PHT

    phase 2 small molecule active

    1 trial

  6. 0.5% Ivermectin lotion

    United Therapeutics Europe Ltd

    Pediculosis Capitis

    phase 2 small molecule completed

    1 trial

  7. 0.9% Sodium Chloride Injection

    GlaxoSmithKline

    Non-alcoholic Fatty Liver Disease

    phase 2 small molecule active

    1 trial

  8. 0.9% Sodium Chloride Injection, mRNA-3705

    Moderna Biotech Spain

    Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency

    phase 2 small molecule active

    1 trial

  9. 0.9% Sodium Chloride for Injection (Fresenius Kab) sourced locally by sites, AP-101

    Lacuna Pharma Pty Ltd

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  10. 0.9% sodium chloride - inhalation solution, ARO-MUC5AC Inhalation Solution

    Arrowhead Pharmaceuticals Ireland Limited

    Asthma and Chronic obstructive pulmonary disease

    phase 2 small molecule active

    1 trial

  11. 1% tenofovir gel

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 2 small molecule completed

    1 trial

  12. 100U EV71 vaccine with adjuvant

    Sinovac Research and Development Co.,

    Infection, Viral, Enterovirus

    phase 2 mab completed

    1 trial

  13. 177Lu PSMA I&T solution for injection

    Wuhan Createrna Science and Technology Co., Ltd

    Recurrent grade 3 and grade 4 glioma

    phase 2 small molecule active

    1 trial

  14. 2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy

    The First People's Hospital of Lianyungang

    Cervical Cancer Stage IVA

    phase 2 other active

    1 trial

  15. 400 U EV71 vaccine with adjuvant

    Sinovac Research and Development Co.,

    Infection, Viral, Enterovirus

    phase 2 mab terminated

    1 trial

  16. 400 microgrammes GSK961081

    Theravance Biopharma Ireland Umited

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  17. 400 µg of MBX 2109 once-weekly by subcutaneous injection

    MBX Biosciences

    Hypoparathyroidism

    phase 2 small molecule active

    1 trial

  18. 4D-125 IVT Injection

    4D Molecular Therapeutics

    X-Linked Retinitis Pigmentosa

    phase 2 mab active

    1 trial

  19. 5% MInoxidil milky lotion

    Hospital Authority, Hong Kong

    Objective (Goal)

    phase 2 small molecule active

    1 trial

  20. 5% Nu-3 gel

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Infection

    phase 2 small molecule active

    1 trial

  21. 5-FU medac 50 mg/ml, Injektionslösung, ELVN-002, BENDAFOLIN 10 mg/ml Injektionslösung, ELVN-002, ELVN-002, ELVN-002, ELVN-002, Benda-5 FU 50 mg/ml Injektionslösung, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ELVN-002, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, HALAVEN 0.44 mg/ml solution for injection, Capecitabin "Zentiva", filmovertrukne tabletter, ELVN-002, Herceptin 150 mg powder for concentrate for solution for infusion, Capecitabine Ac

    Enliven Therapeutics

    Solid Tumors, Colorectal Cancer and Breast Cancer

    phase 2 small molecule active

    1 trial

  22. 5-Fluorouracil (5-FU)

    HALOZYME THERAPEUTICS, INC.

    Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

    phase 2 small molecule completed

    1 trial

  23. 611 300 mg Q2W

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  24. 68Ga-FAPI-46 PET-CT for molecular assessment of fibroblast activation and risk assessment in solid tumors (FAPI Basket)

    Istituto Gentili S.r.l.

    Solid tumors

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources